Canadian Adverse Reaction Newsletter
Volume 12 · Number 1 · January 2002
Marketed Health Products Directorate
Heath Products and Foods Branch
In This Issue
Statins: rhabdomyolysis and
myopathy
Alendronate: suspected pancreatitis
HIV-associated lipodystrophy
syndrome
Summary of drug advisories
Communiqué
Consumers and health professionals may contact us toll free at:
Telephone: 866 234-2345
Fax: 866 678-6789
Statins: rhabdomyolysis
and myopathy
Statins belong to a class of cholesterol-lowering agents that inhibit
the liver enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.
The use of HMG-CoA reductase inhibitors has been associated with severe
myopathy, including rhabdomyolysis.1-6
The statins approved for sale in Canada include atorvastatin (Lipitor),
cerivastatin (Baycol), fluvastatin (Lescol), lovastatin (Mevacor, Apo-Lovastatin,
Gen-Lovastatin), pravastatin (Pravachol, Apo-Pravastatin, Bio Pravastatin,
Lin-Pravastatin) and simvastatin (Zocor). On Aug. 8, 2001, Bayer Inc.
voluntarily suspended the marketing and distribution of Baycol in Canada.7,8
The continued scrutiny of postmarketing reports of rhabdomyolysis, including
related deaths, has revealed an increased reporting rate of rhabdomyolysis
with Baycol than with the other statins, especially when gemfibrozil is
prescribed concurrently.7
The Canadian Adverse Drug Reaction Monitoring Program (CADRMP) has received
reports of rhabdomyolysis or myopathy with all statins approved for sale
in Canada (Table 1). In severe cases, rhabdomyolysis
can result in kidney failure.8 The statin
cases of rhabdomyolysis outlined in Table 1 with which
acute renal failure was also reported were: atorvastatin (2 cases), cerivastatin
(15), lovastatin (5), pravastatin (1) and simvastatin (2). The reports
of rhabdomyolysis with a fatal outcome were: atorvastatin (1), cerivastatin
(2) and lovastatin (1).
Table
1: Rhabdomyolysis, myopathy and increased CPK reactions associated with
statins as reported to the CADRMP from date marketed in Canada to Aug.
24, 2001
Various factors may increase the risk of myopathy and rhabdomyolysis
with statins. Rhabdomyolysis can occur with all statins when used alone
and particularly when combined with other drugs or chemicals that are
themselves myotoxic or that elevate the concentrations of the statin to
the toxic range.9 Evidence suggests that
myopathy is dose-dependent,9 and it is usually
recommended that statin therapy be initiated at lower therapeutic doses.1-6
Combined use with niacin in lipid-lowering doses, with fibric acid derivatives
such as bezafibrate, fenofibrate and gemfibrozil,1-6
or with drugs or foods that inhibit the cytochrome P450 (CYP450) system,
particularly CYP3A4, (including but not limited to cyclosporins, macrolide
antibiotics, antidepressants such as nefazodone, azole antifungals and
grapefruit juice) can potentially increase the toxicity of statins.1,3,
5,6,9 Atorvastatin,
cerivastatin, lovastatin and simvastatin are metabolized mainly by CYP3A4.10
Lovastatin and simvastatin may particularly be affected by the inhibition
of first-pass metabolism, which could result in 10- to 20-fold elevations
(oral availability increasing from 5% to 100%) in steady-state concentrations
with a marked potential for drug toxicity.9
Pravastatin is not metabolized by CYP3A4 to a clinically significant extent.2
Fluvastatin is metabolized mainly by CYP2C94,10
and would have a different spectrum of interactions than would statins
metabolized by CYP3A4.9 Further information
concerning drug interactions may be obtained from the product monograph
of each statin.1-6 In addition, caution should
be exercised when using statins in patients with impaired renal function.1-6
The product monograph of each statin has no clear recommendation for
biochemical monitoring of muscle effect (creatine phosphokinase [CPK]
measurement). In the absence of symptoms, there is no evidence to suggest
that routine monitoring of plasma CPK activity is of benefit.10
However, further investigation is required to provide more definitive
monitoring guidelines. It was suggested in a recent review article10
that it is important to measure the baseline CPK level at least once before
starting statin therapy.
Patients taking a statin or a fibrate should be made aware of rhabdomyolysis
as a potential side effect. They should be advised to report promptly
any signs of muscle problems (i.e., unexplained muscle weakness, tenderness
or pain, either occurring at rest or exacerbated by exercise) and dark
urine, particularly if these symptoms are accompanied by malaise or fever.
Written by: Duc Vu, MSc, PhD, Mano Murty, MD, CCFP, FCFP, and
Marielle McMorran, BScPharm, Bureau of Licensed Product Assessment.
References
1.Mevacor, lovastatin
tablets [product monograph]. Kirkland (QC): Merck Sharp & Dohme
Canada; 1998 Sept 10.
2.Pravachol, pravastatin
sodium tablets [product monograph]. Montréal (QC): Bristol-Myers
Squibb Canada; 2000 Feb 22.
3.Zocor, simvastatin
tablets [product monograph]. Kirkland (QC): Merck Frosst Canada; 1999
Aug 23.
4.Lescol, fluvastatin
sodium capsules [product monograph]. Dorval (QC): Novartis Pharmaceuticals
Canada; 2001 Feb 14.
5.Lipitor, atorvastatin
calcium tablets [product monograph]. Kirkland (QC): Pfizer Canada;
2001 May 31.
6. Baycol, cerivastatin
sodium tablets [product monograph]. Etobicoke (ON): Bayer; 2000 Dec
27.
7. Market withdrawal
of Baycol (cerivastatin) [Dear Healthcare Professional letter]. Toronto
(ON): Bayer; 2001 Aug 8. Available: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2001/baycol_2_hpc-cps_e.html (accessed 2001 Dec
5).
8. Voluntary withdrawal
of Baycol [public advisory]. Ottawa (ON): Health Canada; 2001 Aug
10. Available: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2001/2001_89_e.html
(accessed 2001 Dec 5).
9. Herman RJ. Drug interactions
and the statins. CMAJ 1999;161(10):1281-6. Available: http://www.cma.ca/cmaj/vol-161/issue-10/1281.htm
(accessed 2001 Dec 5).
10. Baker SK, Tarnopolsky
MA. Statin myopathies: pathophysiologic and clinical perspectives [review].
Clin Invest Med 2001;24(5):258-71.
Alendronate: suspected pancreatitis
Alendronate (Fosamax) is a bisphosphonate inhibitor of bone resorption
indicated in Canada for the treatment of Paget's disease of bone and osteoporosis,
including glucocorticoid-induced osteoporosis in men and women. It is
also used to prevent osteoporosis in postmenopausal women and in patients
receiving glucocorticoids.1
Between December 1995, when alendronate was marketed in Canada, and
Aug. 31, 2001, the Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
received 6 reports of suspected pancreatitis associated with alendronate
(Table 1). Pancreatitis can be a serious and life-threatening
condition.2 The current product monograph
for Fosamax does not mention pancreatitis as a possible side effect.1
The causal relation between alendronate and pancreatitis is difficult
to establish because of the limited information in the reports received.
Onset ranged from 13 days to several years after starting alendronate
therapy. Furthermore, it is unknown whether a rechallenge was done in
any of the cases. Case 3 may emphasize a causal relation (Table
1). The acute pancreatitis resolved after the alendronate therapy
was stopped. The patient lacked the most common causes of pancreatitis
(alcohol abuse and gallstones)2 and was not
reported to have taken concomitant medications. Numerous drugs have been
implicated as the cause of acute pancreatitis2,3
and their use may be a source of confounding factors in some of the other
cases (Table 1).
Since there is underreporting of adverse drug reactions (ADRs) and patient
exposure is unknown, the incidence of alendronate-associated pancreatitis
cannot be derived from the reported cases. The mechanism involved and
associated risk factors are unknown.
If drug-induced pancreatitis is suspected in a patient with abdominal
pain and increased levels of pancreatic enzymes without a medical cause,
it may resolve once the suspected drug is withdrawn.2
Continued reporting to the CADRMP of the full details of suspected cases
will aid in further assessing this suspected adverse reaction.
Table 1:
Summary of reports of suspected pancreatitis associated with alendronate
submitted to the CADRMP between December 1995 and Aug. 31, 2001
Written by: Barbara Cadario, BSc, BScPhm, MSc, BC Regional Adverse
Drug Reaction Centre and BC Drug and Poison Information Centre, Vancouver,
BC.
References
1. Fosamax, alendronate
sodium [product monograph]. Kirkland (QC): Merck Frosst Canada; 2001
Apr 2.
2. Underwood TW, Frye
CB. Drug-induced pancreatitis. Clin Pharm 1993;12:440-8.
3. Bergholm U, Langman
M, Rawlins M, Gaist D, Andersen M, Edwards IR, et al. Drug-induced acute
pancreatitis. Pharmacoepidemiol Drug Safety 1995;4:329-34.
HIV-associated
lipodystrophy syndrome: overview and summary of case reports
HIV-associated lipodystrophy syndrome (LDS) is a disorder in HIV-infected
patients receiving highly active antiretroviral therapy.1-3
It presents as a range of clinical (morphologic) and metabolic
changes. The following clinical changes have been described: body fat
redistribution such as visceral adiposity (fat gain within the abdomen,
breasts, over the dorsocervical spine and other lipomata) and peripheral
lipoatrophy (fat loss in the face, limbs, buttocks). The metabolic changes
have included hypertriglyceridemia, hypercholesterolemia, insulin resistance,
type 2 diabetes mellitus, impaired glucose tolerance and lactic acidemia.1,2,4
The term "lipodystrophy" has been used to describe fat loss, fat redistribution
and, on a broader level, both clinical and metabolic features of HIV-associated
LDS.2
The pathogenesis of LDS is unknown.1 However,
it has been associated with combination antiretroviral therapy including
protease inhibitors and nucleoside reverse transcriptase inhibitors, the
latter having been linked to mitochondrial toxicity.1-3
As well, it has been suggested that LDS features are the result of chronic
HIV infection, chronic immunodeficiency or recovery from immune dysfunction.5
No validated case definition of LDS has yet been formulated. However,
a working case definition has been described as having at least one clinical
feature and at least one metabolic abnormality, and no AIDS-defining
event or other severe clinical illness or use of anabolic steroids, glucocorticoids
or immune modulators within 3 months of assessment.4
The CADRMP database was searched for LDS-related ADRs up to Aug. 31,
2001. The search focused on metabolic and nutritional disorders and endocrine
disorders associated with antiretroviral drugs containing abacavir, amprenavir,
delavirdine, didanosine, efavirenz, indinavir, lamivudine, lopinavir,
nelfinavir, nevirapine, ritonavir, saquinavir (base and mesylate), stavudine
or zalcitabine. A total of 119 ADR reports were found, of which only 4
met the LDS working case definition (Table 1).
In addition to the cases described in Table 1, other
reports found in the database denoted potential LDS: lipodystrophy (3
cases) and fat disorder (13 cases). These additional cases did not clearly
report the presence of combined clinical and metabolic features, possibly
because of the available scientific knowledge at that time.
Retrospective studies have reported a prevalence of LDS of 17%-84% among
HIV-infected cohorts receiving highly active antiretroviral therapy.6
It is clear that LDS is highly underreported to Health Canada. Reports
of ADRs are an important source of potential new and undocumented signals.
To this end, a pilot project underway within the Therapeutic Products
Directorate is promoting increased reporting to Health Canada of ADRs
in HIV-infected patients.7 Its purpose is
to develop alternative methods and formats for clinicians and patients
to report ADRs. One such method proposed for testing in the pilot project
is the electronic entry of ADR data as part of the everyday practice of
clinicians.
Table
1: Cases of potential lipodystrophy syndrome* associated with antiretroviral
drugs reported to the CADRMP up to Aug. 31, 2001
Written by:Susanne Reid, BSc, RT, Bureau of Licensed Product Assessment.
References
1. Carr A, Cooper DA.
Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
2. Qaqish RB, Fisher
E, Rublein J, Wohl DA. HIV-associated lipodystrophy syndrome. Pharmacotherapy
2000;20(1):13-22.
3. Brinkman K, Smeitink
JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue
reverse transcriptase inhibitors is a key factor in the pathogenesis of
antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5.
4. Carr A, Samaras K,
Thorisdottir A, Kaufmann GR, Chisholm J, Cooper DA. Diagnosis, prediction,
and natural course of HIV-1 protease-inhibitor-associated lipodystrophy,
hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet
1999;353:2093-9.
5. Miller J, Carr A,
Smith D, Emery S, Law MG, Grey P, Cooper DA. Lipodystrophy following antiretroviral
therapy of primary HIV infection. AIDS 2000;14:2406-7.
6. Mauss S. HIV-associated
lipodystrophy syndrome. AIDS 2000;14(Suppl 3):S197-S207.
7. Enhanced post
marketing surveillance of HIV/AIDS drug therapies -- pilot project. Phase
1: Proof of concept summary & evaluation report. Ottawa: Therapeutic
Products Directorate, Health Canada, in partnership with the University
of Ottawa, Health Services; 2000. Available: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/hiv-aids_1_e.pdf
(accessed 2001 Dec5).
Summary of health professional and consumer
advisories
issued since Aug. 18, 2001
|
Date |
Product |
Subject and Web address |
|
Nov 29 |
Glitazones (Actos
and Avandia) |
Patient safety information - congestive heart
failure |
|
|
|
Nov 26 |
Eprex
(epoetin alfa) |
Pure red blood cell aplasia |
|
|
|
Nov 13 |
Avandia
(rosiglitazone) |
Congestive heart failure |
|
|
|
Nov 6 |
Actos
(pioglitazone) |
Congestive heart failure |
|
|
|
Oct 23 |
Remicade
(infliximab) |
Congestive heart failure |
|
|
|
Oct 5 |
Aristolochic acid |
Additional products containing aristolochic
acid and toxicity |
|
|
|
Sept 24 |
Zyban
(bupropion) |
Seizures, allergic reactions, drug interactions
|
|
|
|
Sept 17 |
Aristolochic acid |
Recall of products containing aristolochic
acid |
|
|
|
Sept 13 |
Topamax
(topiramate) |
Acute myopia and secondary angle closure
glaucoma |
|
|
|
Sept 10 |
Carnitor
(levocarnitine) |
Precautions related to use in end-stage renal
disease |
|
|
|
September |
Gleevec
(imatinib) |
Notice of Compliance with Conditions (NOC/C)
|
|
|
|
Aug 27 |
Zirconia |
Recall of ceramic femoral heads for use in
hip replacement |
Newsletter and drug advisories by email
Join the Health Prod Info mailing list to subscribe electronically to
this newsletter and to receive notices of health professional and consumer
advisories for therapeutic products.
Go
to http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/index_e.html and click
on "subscribe".
COMMUNIQUÉ
The CADRMP wishes to provide feedback and increase awareness of recently
reported ADRs. The following cases have been selected on the basis of
their seriousness, or the fact that the reactions do not appear in the
official Canadian product monograph. (Reactions are expressed based on
the "preferred term" in the World Health Organization Adverse Reaction
Dictionary.)
Ibuprofen pediatric oral liquid: gastrointestinal bleeding
Two reports have been received involving children aged 14 months and
2½ years who vomited "large blood clots" (1 case) and passed "black,
tarry, foul-smelling stool" followed by "nonspecific abdominal pain, irritability
and lethargy" (1 case) after receipt of ibuprofen as a pediatric oral
liquid. Symptoms were reported to have occurred after only a few doses
(as early as after the first dose in 1 case).
If you have observed any suspected ADRs with the drug in the Communiqué,
please report them to the :
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Adverse Reaction Information Unit
Bureau of Licensed Product Assessment
AL: 0201C2, Ottawa, ON K1A 1B9
Tel: (613) 957-0337 Fax: 613 957-0335
Consumers and Health Professionals may contact us Toll free at:
Tel: 866 234-2345, Fax: 866 678-6789
Email: cadrmp@hc-sc.gc.ca
Please Note: A voluntary reporting system thrives
on intuition, lateral thinking and open mindedness. Most adverse drug
reactions (ADRs) can only be considered to be suspicions, for which a
proven causal association has not been established. Because ADRs are under
reported and because a definite causal association cannot be determined,
spontaneous ADR reports cannot be used to estimate the incidence of adverse
reactions. ADRs are nevertheless valuable as a source of potential new
and undocumented signals. Health Canada does not assume liability for
the accuracy or authenticity of the ADR information contained in the newsletter
articles. Furthermore, the Therapeutic Products Directorate monitors and
assesses suspected ADRs as a means of continuously evaluating drug safety
profiles. Regulatory decisions are not made within the context of this
newsletter. |
The Canadian Adverse Drug Reaction Newsletter is prepared and funded
by the Therapeutic Products Directorate, Health Canada, and is published
quarterly in CMAJ.
Newsletter Editors: Ann Sztuke-Fournier, BPharm, and Marielle
McMorran, BScPharm, Bureau of Licensed Product Assessment.
We thank the Expert Advisory Committee on Pharmacovigilance, the ADR
Regional Centres and the Therapeutic Products Directorate for their contributions
to these articles. The contributions of Diane A. Bergeron, BPharm, Consulting,
are also greatly appreciated.
© Her Majesty the Queen in Right of Canada, 2002. This publication
may be reproduced without permission provided the source is fully acknowledged.
Aussi disponible en français.
Reporting Adverse Drug Reactions:
To report a suspected adverse drug reaction (ADR) for drug products marketed
in Canada, please complete a copy of the ADR Reporting Form, included in the Compendium of Pharmaceuticals
and Specialties (CPS), which is also available on the Health Canada
Website.
Complete the reporting form and send it to the CADRMP or to one of the
participating Regional Centres mentioned below.
![image of ADR Reporting form](/web/20061210204707im_/http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/images/adr_reporting_form_image.gif)
List of Regional Adverse Drug Reaction Reporting
Centres
British Columbia
BC Regional ADR Centre
c/o BC Drug and Poison
Information Centre
1081 Burrard St.
Vancouver BC V6Z 1Y6
Tel 604 806-8625
Fax 604 806-8262
adr@dpic.bc.ca
Ontario
Ontario Regional ADR Centre
LonDIS Drug Information Centre
London Health Sciences Centre
339 Windermere Rd.
London ON N6A 5A5
Tel 519 663-8801
Fax 519 663-2968
adr@lhsc.on.ca
New Brunswick, Nova Scotia, Prince
Edward Island and Newfoundland
Atlantic Regional ADR Centre
C/O Queen Elizabeth II Health
Sciences Centre
Drug Information Centre
1796 Summer St., Rm. 2421
Halifax NS B3H 3A7
Tel 902 473-7171
Fax 902 473-8612
adr@cdha.nshealth.ca
Saskatchewan
Sask ADR Regional Centre
Dial Access Drug Information Service
College of Pharmacy and Nutrition
University of Saskatchewan
110 Science Place
Saskatoon SK S7N 5C9
Tel 306 966-6340 or 800 667-3425
FSax 306 966-6377
vogt@duke.usask.ca
Québec
Québec Regional ADR Centre
Drug Information Centre
Hôpital du Sacré-Coeur de
Montréal
5400, boul. Gouin ouest
Montréal QC H4J 1C5
Tel 514 338-2961 or
888 265-7692
Fax 514 338-3670
cip.hscm@sympatico.ca
Other provinces and territories
CADRMP
National ADR Unit
Bureau of Licensed Product Assessment
Finance Building, Tunney's Pasture
AL 0201C2
Ottawa ON K1A 1B9
Tel 613 957-0337
Fax 613 957-0335
cadrmp@hc-sc.gc.ca
Health Professionals and Consumers may report Adverse
Drug Reactions toll-free:
Tel: 866 234-2345
Fax: 866 678-6789
Canadian Adverse Drug Reaction Newsletter accessible on
the Web
The Canadian Adverse Drug Reaction Newsletter alerts and informs health
care professionals to adverse drug reactions reported in Canada via the
ADR reporting programme (see above). You may access previous Newsletters
and the Index.
ISSN 1492-8167, Cat. No. H42-4/1-12-1E-IN
|